But is there room for another antibody, given lacklustre sales and Regeneron’s dominance?
Animal toxicity findings with ARO-ENaC come not long after Ionis’s similar setback.
With a Darpin antiviral for treating Covid-19 Molecular Partners hopes to follow Vir’s regulatory path.
A win for Vir’s late-to-the-game antibody and another fail for Roche with Actemra show how developers are still feeling their way in Covid-19.
Hopes for the highly valued biotech’s Covid-19 antibody dim before a more important look at the project’s potential.
A trial testing a combination of Lilly and Vir antibodies is the latest attempt by developers to stay ahead of the virus that causes Covid-19.